<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2444-7986</journal-id>
<journal-title><![CDATA[Revista ORL]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. ORL]]></abbrev-journal-title>
<issn>2444-7986</issn>
<publisher>
<publisher-name><![CDATA[Ediciones Universidad de Salamanca]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2444-79862022000400005</article-id>
<article-id pub-id-type="doi">10.14201/orl.27528</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Actualización en el tratamiento del hipoparatiroidismo posquirúrgico]]></article-title>
<article-title xml:lang="en"><![CDATA[Update on management of postoperative hypoparathyroidism]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ventosa-Viña]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuéllar-Olmedo]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Crespo-Soto]]></surname>
<given-names><![CDATA[Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacio-Mures]]></surname>
<given-names><![CDATA[José María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Duque]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lázaro-Martín]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Río Hortega Servicio de Endocrinología ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>13</volume>
<numero>3</numero>
<fpage>239</fpage>
<lpage>246</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2444-79862022000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2444-79862022000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2444-79862022000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN:  Introducción y objetivo: El hipoparatiroidismo posquirúrgico es una complicación frecuente de la cirugía tiroidea y paratiroidea, con consecuencias significativas sobre la salud y calidad de vida. El objetivo de esta revisión es proporcionar una visión actualizada de su prevención, detección precoz y tratamiento.  Síntesis: Tras la tiroidectomía y paratiroidectomía puede aparecer hipoparatiroidismo de forma aguda, especialmente en algunos pacientes de alto riesgo. La determinación de la hormona paratiroidea intacta (PTHi) en el postoperatorio temprano es una herramienta útil en el manejo del paciente. Un nivel de PTHi postoperatoria &lt;10-15 pg/ml, combinado con los niveles de calcemia 24 horas después de la cirugía, ofrece el mejor valor predictivo para hipocalcemia aguda. El hipoparatiroidismo permanente se asocia con morbilidad y deterioro de calidad de vida a largo plazo y debería prevenirse cuando sea posible. El tratamiento convencional incluye calcio oral y metabolitos activos de vitamina D. En caso de hipocalcemia severa o sintomática se precisa calcio intravenoso. El tratamiento debe monitorizarse e incluir educación sanitaria del paciente, para evitar amplias desviaciones de la calcemia. Sin embargo, con la terapia convencional mantener un adecuado control puede representar un desafío. La terapia sustitutiva con hormona paratiroidea recombinante (rhPTH) puede reducir las dosis de calcio y calcitriol necesarias, manteniendo la calcemia y fosfatemia dentro de los rangos recomendados. También parece mejorar el metabolismo óseo y la calidad de vida a largo plazo. Se precisa más información en cuanto a eficacia y seguridad con esta terapia.  Conclusiones: El hipoparatiroidismo posquirúrgico es frecuente. Requiere un diagnóstico temprano, intervención farmacológica y educación del paciente para alcanzar un control óptimo y disminuir el riesgo de complicaciones a largo plazo. La rhPTH parece una opción prometedora para aquellos pacientes que no mantienen la calcemia dentro del objetivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY:  Introduction and objective: Surgical hypoparathyroidism is a common complication following thyroid and parathyroid surgery. It has significant consequences for health and quality of life. The objective of this review is to provide an overview of its prevention, early detection, and treatment.  Synthesis: Acute hypoparathyroidism can occur after thyroidectomy and parathyroidectomy, especially in high-risk patients. Measurement of early postoperative intact parathyroid hormone (PTHi) can help guide patient management. A postoperative PTHi &lt; 10-15 pg/ml combined with serum calcium assay testing 24 hours after surgery yielded the highest diagnostic accuracy for predicting acute hypocalcemia. Permanent hypoparathyroidism is associated with long-term morbidity and poor quality of life, and should be prevented whenever possible. Conventional treatment consist of oral calcium and active vitamin D analogs. For more severe or symptomatic hypocalcemia it is necessary intravenous calcium. Treatment require monitoring and patient education to avoid wide swings in serum calcium. However, with standard therapy, maintaining an adequate control often presents a therapeutic challenge. Recombinant human parathyroid hormone (rhPTH) replacement can lower the doses of calcium and active vitamin D analogs required, while maintaining serum calcium and phosphate levels within the recommended therapeutic ranges. It may improve bone metabolism and quality of life on the long term. Additional data on safety and efficacy are needed.  Conclusions: Postoperative hypoparathyroidism is common. It requires early diagnosis, pharmacologic intervention and patient education to achieve optimal control and lower the risk of long-term complications. rhPTH seems to be an effective option for those patients who do not stably mantein their calcium in the target range.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hipoparatiroidismo]]></kwd>
<kwd lng="es"><![CDATA[hipoparatiroidismo posquirúrgico]]></kwd>
<kwd lng="es"><![CDATA[hipocalcemia]]></kwd>
<kwd lng="es"><![CDATA[hormona paratiroidea]]></kwd>
<kwd lng="es"><![CDATA[tiroidectomía]]></kwd>
<kwd lng="en"><![CDATA[hypoparathyroidism]]></kwd>
<kwd lng="en"><![CDATA[postoperative hypoparathyroidism]]></kwd>
<kwd lng="en"><![CDATA[hypocalcemia]]></kwd>
<kwd lng="en"><![CDATA[parathyroid hormone]]></kwd>
<kwd lng="en"><![CDATA[thyroidectomy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edafe]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Antakia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Laskar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Uttley]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Balasubramanian]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of predictors of post-thyroidectomy hipocalcemia]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>2014</year>
<volume>101</volume>
<page-range>307-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huguet]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Varsavsky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocolo de diagnóstico y manejo de hipocalcemia en postoperatorio de tiroides]]></article-title>
<source><![CDATA[Rev Osteoporos Metab Miner]]></source>
<year>2020</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karakas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Osei-Agyemang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schlosser]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zielke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rothmund]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of parathyroid auto transplantation during bilateral surgery for Graves disease on postoperative hypocalcemia]]></article-title>
<source><![CDATA[Endcor Regul]]></source>
<year>2008</year>
<volume>42</volume>
<page-range>39-44</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gil-Carcedo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cuéllar]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hormona paratiroidea intacta como predictor temprano de hipocalcemia en la tiroidectomía total]]></article-title>
<source><![CDATA[Rev. ORL]]></source>
<year>2016</year>
<volume>7</volume>
<numero>^sSupl. 1</numero>
<issue>^sSupl. 1</issue>
<supplement>Supl. 1</supplement>
<page-range>1-42</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bancos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Kasperbauer]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teriparatide therapy and reduced postoperative hospitalization for postsurgical Hypoparathyroidism]]></article-title>
<source><![CDATA[JAMA Otolaryngol Neck Surg]]></source>
<year>2015</year>
<volume>141</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>822-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orloff]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiseman]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bernet]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fahey III]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaha]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Shindo]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention and management in adults]]></article-title>
<source><![CDATA[Thyroid]]></source>
<year>2018</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>830-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Shoack]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bouillon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Thakker]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hypoparathyroidism: summary statement and guidelines]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2016</year>
<volume>101</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2273-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollerslev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rejnmark]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Marcocci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shoback]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Sitges-Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Biesen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2015</year>
<volume>173</volume>
<page-range>G1-G20</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shrader]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chornic hypoparathyroidism]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2012</year>
<volume>97</volume>
<page-range>391-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannstadt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Vokes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Ranganath]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2013</year>
<volume>1</volume>
<page-range>275-83</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy of Hypoparathyroidism With PTH (1&#8211;84): A Prospective Six Year Investigation of Efficacy and Safety]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2016</year>
<volume>101</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2742-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tabacco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tay]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Omeragic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Majeed]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2019</year>
<volume>104</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2748-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tay]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Tabacco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Omeragic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Majeed]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy or hypoparathyroidism with rh PTH (1-84): a prospective, 8 year investigation of efficacy and safety]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2019</year>
<volume>104</volume>
<page-range>5601-10</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Van Uum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Bollersiev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Standards of care for hypoparathyroidism in adults: a Canadian and international consensus]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2019</year>
<volume>180</volume>
<page-range>1-23</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oleaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parente]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Paja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Carcedo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Escolá]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resumen ejecutivo del documento de consenso SEORL CCC-SEEN sobre hipoparatiroidismo postiroidectomía]]></article-title>
<source><![CDATA[Endocrinol Diabetes Nutr]]></source>
<year>2019</year>
<volume>66</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>459-63</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazaure]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical Hypoparathyroidism]]></article-title>
<source><![CDATA[Endocrinol Metab Clin N Am]]></source>
<year>2018</year>
<volume>47</volume>
<page-range>783-96</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
